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Available online 22 December 2015Degenerative joint diseases such as osteoarthritis are characterised by aberrant region-speciﬁc bone formation
and abnormal bonemineral content. A recent study suggested a role for the complement membrane attack com-
plex in experimental models of osteoarthritis. Since CD59a is the principal regulator of the membrane attack
complex in mice, we evaluated the impact of CD59a gene deletion upon maintenance of bone architecture.
In vivo bonemorphology analysis revealed that male CD59a-deﬁcient mice have increased femur length and cor-
tical bone volume, albeit with reduced bone mineral density. However, this phenomenon was not observed in
female mice. Histomorphometric analysis of the trabecular bone showed increased rates of bone homeostasis,
with both increased bone resorption and mineral apposition rate in CD59a-deﬁcient male mice. When bone
cells were studied in isolation, in vitro osteoclastogenesis was signiﬁcantly increased in male CD59a-deﬁcient
mice, although osteoblast formation was not altered.
Our data reveal, for the ﬁrst time, that CD59a is a regulator of bone growth and homeostasis. CD59a ablation in
male mice results in longer and wider bones, but with less density, which is likely a major contributing factor
for their susceptibility to osteoarthritis. These ﬁndings increase our understanding of the role of complement
regulation in degenerative arthritis.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Micro-CT1. Introduction
The balanced activity of bone-forming osteoblasts and bone-
resorbing osteoclasts maintains bone homeostasis [1]. Mechano-
signalling and systemicmediators activate resting bone surfaces, induce
remodelling, and modulate the recruitment and maturation of osteo-
clast precursor cells [2–5]. Osteoclastogenesis and consequential re-
sorption of bone induces osteoblast maturation and the secretion of
bone matrix and hydroxyapatite [6]. Osteoclast and osteoblast function
is therefore coupled during bone remodelling. In 1991, Sato et al. discov-
ered that osteoblast–osteoclast cross-talk is modulated by complement
components [7]. The complement (C) system consists of activation
pathways and the membrane attack complex (MAC). The MAC isgy, Institute of Infection and
rk, Cardiff CF14 4XN,Wales, UK.
. This is an open access article underformed from complex assembly of C5b, C6, C7, C8, and multiple copies
of C9; once formed, itwill create amembrane porewhich can lyse target
cells. This assembly is inhibited by CD59 expressed on almost all autol-
ogous cells [8,9]. The complement system is a vital component of innate
immunity with diverse roles; recent studies support its potential in-
volvement in regulating bone homeostasis. C3-deﬁcient bone marrow
cells have dysfunctional osteoclast differentiation [10] whereas wild
type (WT) bone marrow stimulation with C3a or C5a with IL-1β causes
elevated osteoclast differentiation [11].
There is indirect evidence for the regulatory capacity of complement
proteins in bonemetabolism. This can be seen in human rheumatoid ar-
thritis [12], and experimental models of arthritis such as antigen-
induced arthritis [13], collagen-induced arthritis [14], and induced oste-
oarthritis (OA) [15]. In each case, the complement system is a potent
trigger and ampliﬁer of local and systemic inﬂammation that causes
bone atrophy and aberrant bone apposition. Complement proteins are
also expressed in a speciﬁc spatial arrangement in the growth platethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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related genes during osteoblast differentiation has also been described
[17]. Furthermore, osteoblasts express the central complement proteins
C3 andC5 and their corresponding receptors C3aR andC5aR [11]. There-
fore, complement and bone homeostasis are intricately linked.
The physiological impact of MAC activation upon bone, osteoclast
differentiation, and osteoblast maturation has been largely neglected.
However, a recent study usingmurine experimentalmodels of OA iden-
tiﬁed MAC as a potential regulator of cartilage degeneration and osteo-
phyte formation [15]. In OA models, mice lacking the CD59a gene
(CD59a−/−) exhibited exacerbated cartilage erosion and synovitis,
whereas deﬁciency in C5 or C6 protected mice from cartilage loss and
synovitis. Furthermore, C5 and C6 deﬁciency prevented, whereas
CD59a deﬁciency augmented osteophyte formation [15].
Research into complement regulators has been greatly advanced in
genetically engineered mouse models [15]. Wang et al. showed that
CD59a−/−mice can develop osteoarthritis spontaneously as evidenced
by cartilage loss, hence creating amodel highly comparable to humandis-
ease [15].We set out to explore the impact of CD59auponbone formation
and age-related changes to bone structure inmice. Our data reveal, for the
ﬁrst time, that CD59a is a regulator of bone growth and homeostasis.
2. Materials and methods
2.1. Animals
Experiments were performed using WT and CD59a−/− [18] mice
(C57BL/6J). Animals (8, 20, and 50 weeks of age) were bred in-house
and maintained in conventional housing. Procedures were executed in
accordance with UK Home Ofﬁce Project Licence PPL-30/2361. Animals
were randomly allocated into study groups.
2.2. Assessment of bone morphology
Hind limbs were harvested and ﬁxed in 70% methanol. Femoral
length was determined from contact X-rays using the KODAK In vivo
Imaging System FX Pro (Carestream Health). Femoral width was mea-
sured using a digital calliper. Structure of distal femoral bones was
assessed by micro-CT (Skyscan-1072 X-Ray microtomograph). High-
resolution scans with an isotropic voxel size of 10.8 μmwere acquired
(49.6 kV, 200.8 μA, 1 mm aluminium ﬁlter, 0.45° rotation angle). A
1 mm section of trabecular bone from the metaphysis was analysed,
starting 1 mm below the reference point within the growth plate.
Cortical bone architecture was evaluated 3 mm below the same
reference point (1 mm section measured). The scans were reconstruct-
ed using NRecon and analysed using the CTAn software package
(Bruker-Micro-CT). For calculation of the bone mineral density (BMD),
calibration of the Skycan CT systemwas performedwith known density
calcium hydroxyapatite phantoms (0.25 and 0.75 g/cm3).
2.3. TRAP staining for osteoclasts
Fixed femora were embedded in methylmethacrylate [19].
Osteoclasts were identiﬁed on longitudinal sections (5 μm) of the distal
femurs using tartrate-resistant acid phosphatase (TRAP) staining [20].
TRAP stainingwas photographedusing aAperio ScanScope CS slide scan-
ner (Leica Biosystems) and analysed using Image J-based software [21].
2.4. Immunohistochemistry for osteopontin
Hind limbs were ﬁxed in neutral buffered formalin, decalciﬁed in 10%
formic acid for 3weeks at 4 °C, embedded in parafﬁnwax, and cut in 7 μm
thick sections. Osteopontin (OPN) expression was visualised using an
ImmPRESS Detection Kit (Vector Labs) as permanufacturer's instructions
adding 1 μg/ml of mouse anti-OPN antibody (AKm2A1, Santa Cruz) or
isotype control (MOPC-31C, BD). Sections were counterstained withhaematoxylin. Non-overlapping areas at ×40 magniﬁcation were ran-
domly selected for analysis using Image J-based macros [21].
2.5. Histomorphometric analysis of bone formation
Osteoid was observed in methylmethacrylate embedded sections
after staining with von Kossa/van Gieson reagents [19]. Mice received
two intra-peritoneal injections of calcein (10 mg/kg dissolved in 2%
Na2HCO3 in PBS) 4 and 1 days before sacriﬁce. Calcein double labelling
was quantiﬁed in methylmethacrylate embedded sections counter-
stained with Aniline blue (0.3 mg/ml, pH 7.5).
2.6. In vitro osteoclastogenesis assay
Femurs were harvested from mice and the proximal ends removed
to collect bone marrow cells (BMC) by centrifugation [22]. BMC were
resuspended in α-MEM containing 10% heat-inactivated FCS and
50 units/ml penicillin–streptomycin (growth medium). BMC
(6.4 × 104)were added to 6mmglass coverslips in petri-dishes. Follow-
ing 2 h incubation at 5% CO2 and 37 °C, non-adherent cells were re-
moved by washing in fresh medium and coverslips were transferred
into wells (24-well plate) withmedia containing 25 ng/ml macrophage
colony-stimulating factor (M-CSF) with or without 2 ng/ml RANKL
(both R&D Systems). Media was exchanged on day 3 and cells were
ﬁxed in acetone on day 7. TRAP staining was performed according to
manufacturer's instructions (acid phosphatase kit, Sigma–Aldrich).
Five ﬁelds of view on each glass coverslip at ×40 objective magniﬁca-
tion were counted for total cells and TRAP-positive multinucleated
cells (≥2 nuclei) [23].
2.7. Quantiﬁcation of CXCL1/mKc by enzyme-linked immunosorbent assay
Murine keratinocyte-derived cytokine (mKc) levels were
quantiﬁed from osteoclastogenesis assay supernatants following
the manufacturer's protocol (R&D Systems).
2.8. In vitro osteoblast formation assay
BMC were harvested as described above and osteoprogenitors cul-
tured inα-MEM containing 20% FCS, 50 units/ml penicillin–streptomycin
(expansionmedium). Once conﬂuent, cells were gently scraped from the
culture surface and re-seeded at 4 × 104 cells/well in 12-well plates. After
24 h, medium was replaced with growth media supplemented with
10 mM β-glycerophosphate, 50 μg/ml ascorbic acid, and 10 nM dexa-
methasone (mineralisation medium). Osteoblasts were cultured for
14 days, changing media every 3–4 days. Alkaline phosphatase (ALP) ac-
tivity was identiﬁed using SigmaFast 5-bromo-4-chloro-3-indolyl-phos-
phate (BCIP)/nitro blue tetrazolium (NBT) stain (Sigma–Aldrich).
Alizarin red staining was used to visualise calcium phosphate deposition
in the matrix. Stained plates were scanned and the percentage of the
well covered by ALP-positive cells or mineral determined using Image J.
2.9. Statistical analysis
Analyses were performed with Graphpad Prism v5. A Student t-test
was performed when comparing 2 groups. Two-way ANOVA with
Bonferroni post-tests were utilised when assessing more than 2 groups
with 2 independent variables, respectively.
3. Results
CD59a-deﬁcient mice were shown to develop more severe arthritis
[24]. Although lack of CD59a was studied extensively in disease models
such as arthritis, involvement into homeostatic regulation is poorly de-
ﬁned. Therefore, we examined bone growth in naive CD59a-deﬁcient
mice.
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Bone morphology measurements revealed that femoral length in-
creased with age in both male and female mice (Fig. 1). Signiﬁcantly
longer femurs due to CD59a deﬁciency were observed in male miceFig. 1. Bone growth is increased inmale CD59a-deﬁcientmice. Femurswere X-rayed andwidth
CD59a−/−mouse femurs showing differences in bone size. Scale bar (black): 5 mm. (B) Fem
(D) anterior–posterior femoral shaft width in male WT and CD59a−/− mice. (E), (F), (G), an
shaft width, and anterior–posterior femoral shaft width in age-matched female mice. All valu
⁎P b 0.01, ⁎⁎P b 0.001 versus WT of the same age and sex.(CD59a−/− versus WT) at 8 and 20 weeks of age (Fig. 1A to D). There
was no difference between female WT and CD59a−/− mice at any
time point (Fig. 1E to H). Femoral width (measured in medial-lateral
(Fig. 1C) and anterior–posterior direction (Fig. 1D))was signiﬁcantly in-
creased in male CD59a−/− mice during postnatal growth phasemeasured using digital calliper. (A) Representative images ofmale 8–50-week-oldWT and
oral length in male WT and CD59a−/−mice. (C) Medial–lateral femoral shaft width and
d (H), respectively, show representative x-rays, femoral length, medial–lateral femoral
es are mean ± SEM for six WT (black bars) and CD59a−/− (white bars) mice per group.
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niﬁcant difference in body weight between the two strains; in agree-
ment with published data [18].3.2. Male CD59a-deﬁcient bones have more bone volume which is less
dense
When studying bone architecture, cortical bone volume (cBV) was
signiﬁcantly increased in male and female WT mice over time; at 8
and 20 weeks, cBV was augmented in male CD59a−/− mice (Fig. 2A
and B). Analyses at 50 weeks of age showed small reduction in cBV
(Fig. 2A, upper panel). In females, cBV was comparable at 8 and
20 weeks but decreased signiﬁcantly at 50 weeks of age compared to
WT femurs (Fig. 2A, lower panel). Tissue volume mirrored the increase
in cBV observed in young adult CD59a−/− male mice (signiﬁcant
percentage increase at 8 [20%], and 20 [13%] weeks; not shown).
Cross-sectional thickness (Cs.Th) of cortical bone was not signiﬁcantly
altered in male or female mice (WT versus CD59a−/−). BMD increased
steadily over time in CD59a−/− (male and female) and WT (female
only) mice. In WT male mice, BMD increased between the ages of 8
and 20 weeks and plateaued thereafter. BMD was signiﬁcantly lower
in male mice (CD59a−/− versus WT) at 8 and 20-week-old and female
mice (8 weeks only). In 50-week-old mice (male and female), BMD
was signiﬁcantly higher in CD59a−/− compared toWT (Fig. 2A). Osteo-
phyte formation was not observed but some irregularities at the
subchondral bone occurred at 50 weeks of age (data not shown).
In trabecular bone, percentage bone volume (BV/TV) was signiﬁ-
cantly increased in 8-week-old male CD59a−/− in comparison to age-
matchedWTmice (Fig. 3 A, B; upper plates) due to increased trabecular
thickness (Tb.Th) and trabecular numbers (Tb.N; Fig. 3B and C). Differ-
ences were smaller at 20 weeks and at 50 weeks. Female CD59a−/−
mice did not show any difference in trabecular bone architecture com-
pared to WT controls (Fig. 3 A, B; lower plates). As the bone phenotype
wasmost prominent in youngmale CD59a−/−mice, all remaining stud-
ies excluded female and 50-week-old mice.Fig. 2. Altered cortical bone properties in young-adult CD59a-deﬁcient male mice. Femurs wer
cortical bone from the metaphysis was analysed; starting 3 mm below a reference point with
section that started 1 mm below the same reference point. (A) Cortical bone volume (cBV), c
50-week-old WT (black bars) and CD59a−/− (white bars) mice are shown. All values are mea
same sex. (B) Representative images at corresponding relative positions of 8-week-old WT a
bar (white): 1 mm.3.3. CD59a-deﬁcient mice show increased bone turnover
Bone histomorphometry showed increased osteoclast surface activ-
ity (osteoclast surface/bone surface; OcS/BS) in the secondary
spongiosa of CD59a−/− compared to WT mice at 8 and 20 weeks.
Osteoclast number (OC.N/TA) was signiﬁcantly increased at 20 weeks
only (Fig. 4A and B).
Immunohistochemical staining of femurs for OPN revealed a signiﬁ-
cant 2.4 fold increase in CD59a−/− versus WT mice at 20 weeks only
(Fig. 4C and D). OPN was concentrated in cells that lined the bone
(osteoblasts, osteoclasts, and bone lining cells) and megakaryocytes
(Fig. 4F).
Osteoclasts and osteoblasts act in a dynamic equilibrium as part of
the bone remodelling unit in which osteoblasts secrete bone matrix
[25]. When osteoblast activity was analysed by measuring osteoid sur-
face/bone surface (OS/BS), in male CD59a−/− mice at 8 weeks of age,
OS/BS ratio was two-fold lower than in WT secondary spongiosa
(Figure 5A and B). By 20 weeks, the OS/BS inWTmice was signiﬁcantly
reduced compared to 8 weeks and was not signiﬁcantly different from
the OS/BS in CD59a−/− mice, the latter stayed unchanged between
the time points (Figure 5A). MAR and BFR/BS were determined in vivo
from double labellingwith calcein (Figure 5C–E); bothwere signiﬁcant-
ly increased (MAR: 30%; BFR/BS: 60%) in the secondary spongiosa of
CD59a−/− compared to WT mice at 8 weeks of age. The increased
calcein double label width of CD59a−/− mice is clearly visible in
Figure 5E. No adverse effects were observed.3.4. CD59a deﬁciency promotes osteoclastogenesis but not osteoblast
formation from BMC in vitro
Initially, osteoclasts were generated in ex vivo cultures of BMC from
8–10-week-oldmaleWT and CD59a−/−mice.WhileM-CSF stimulation
alone did not induce osteoclast formation, RANKL supplementation
strongly promoted osteoclastogenesis, visualised as TRAP-positive mul-
tinucleated cells, in cultures from both WT and CD59a−/− micee subjected to micro-CT and cortical bone of the shaft was investigated. A 1 mm section of
in the growth plate. Trabecular bone architecture (reported in Fig. 3) was measured in a
ross-sectional thickness (Cs.Th) and bone mineral density (BMD) of male and female 8–
n ± SEM from a minimum of six mice per group. ⁎P b 0.05; ⁎⁎⁎P b 0.001 versus WT of the
nd CD59a−/−mouse femur cross-sections illustrating variations in bone diameter. Scale
Fig. 3. Structural changes in trabecular bone in male CD59a-deﬁcient mice. The secondary spongiosa of femurs were analysed by micro-CT. A 1 mm section of trabecular bone from the
metaphysis was analysed; starting 1 mm below a reference point within the growth plate. Cortical bone architecture (reported in Fig. 2) was measured in a section that started 3 mm
below the same reference point. (A) Representative images of 8-week-old WT and CD59a−/−mouse femurs, demonstrating marked increase in trabecular bone architecture compared
to controls in male but not female CD59a−/− mice (white boxes highlight region used for measurements). Scale bar (white), 1 mm. (B) Analysis of relative bone volume (BV/TV),
trabecular thickness (Tb.Th), and trabecular number (Tb.N) is shown for 8, 20, and 50-week-old CD59a−/− (white bars) and WT (black bars) mice. All values are mean ± SEM from a
minimum of six mice per group. ⁎⁎P b 0.01 versus WT of the same sex. (C) Representative three-dimensional reconstructions from male 8-week-old WT and CD59a−/−mice. Scale bar
(black), 1 mm.
Fig. 4. Elevated osteoclast activity and increased number of OPN-positive cells in trabecular bone in male CD59a-deﬁcient mice. Femurs were stained with TRAP to identify osteoclasts.
(A) Osteoclast surface per unit bone surface (OcS/BS) and osteoclast numbers per unit tissue area (OC.N/TA) were signiﬁcantly increased in male CD59a−/− (white bars) compared
with WT (black bars) mice. All values are mean ± SEM from a minimum of six mice per group at 8 and 20 weeks of age. ⁎P b 0.05; ⁎⁎P b 0.01 versus WT. (B) Representative images of
TRAP-positive osteoclasts (stained red and highlighted by arrow). M, marrow; Tb, trabecular bone. Scale bar (black), 100 μm. Femurs were stained for OPN by immunohistochemistry.
Summary of analysis in (C) epiphysis, (D) metaphysis, and (E) cortical bone of male WT (black bars) and CD59a−/− (white bars) mice at 8 and 20 weeks. All values are mean ± SEM
from seven mice per group. ⁎⁎P b 0.01, ⁎⁎⁎P b 0.001 versus WT. (F) Representative images of isotype control and OPN staining (brown appearance and highlighted by yellow arrows) at
20 weeks. Megakaryocytes are shown by green arrows. Insets show higher magniﬁcation of staining. M, marrow; Tb, trabecular bone. Scale bar (black), 50 μm.
257A.C. Bloom et al. / Bone 84 (2016) 253–261
Fig. 5. Reduced osteoid and increased bone formation in male CD59a-deﬁcient mice at 8 weeks of age. Femurs were stained with von Kossa/van Gieson to reveal osteoids.
(A) Histomorphometric investigation of femoral osteoid surface over total bone surface (OS/BS) of WT (black bars) and CD59a−/− (white bars) male mice at 8 and 20 weeks. All
values are mean ± SEM from a minimum of six mice per group at 8 and 20 weeks of age. ⁎⁎⁎P b 0.001 versus WT. (B) Representative images of osteoid staining with van Gieson (pink
appearance and highlighted by arrows) at 8 weeks. M, marrow; Tb, trabecular bone. Scale bar (black), 100 μm. (C) Mineral apposition rate (MAR) and (D) bone formation rate (BFR/
BS) calculated from calcein double labelling are shown in WT (black bars) and CD59a−/− (white bars) mice. Bone formation rate is the amount of mineralised bone formed per unit of
time per unit of bone surface. All values are mean ± SEM from four mice per group at 8 weeks of age. ⁎P b 0.05 versus WT. (E) Representative images of calcein double labelling in WT
and CD59a−/−mice. Scale bar (white), 100 μm.
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in BMC from male CD59a−/− compared to WT mice (Figure 6B; 27%).
Subsequent osteoclast differentiation assays conducted using BMC
from age-matched female CD59a−/− compared to WT mice revealed
no alteration in TRAP-positive cell number. Culture supernatants from
male BMC osteoclastogenesis assays were harvested and analysed for
mKc (CXCL1), a marker for osteoclast precursor cell recruitment [26].
Levels of mKc were signiﬁcantly increased in CD59a−/− compared to
WT culture supernatants in response to M-CSF. Co-administration of
M-CSF and RANKL substantially reduced mKc levels compared against
M-CSF alone. Nevertheless, levels of mKc remained signiﬁcantly higher
in CD59a−/− compared to WT samples. To determine whether CD59a
affects osteoblast formation ex vivo, cultures were generated from
enriched BMC osteoprogenitor cells harvested from male mice (8–10-week-old). ALP staining and mineralisation were not signiﬁcantly dif-
ferent between cultures derived from male WT and CD59a−/− mice
after 14 days in mineralisation medium (Figure 6C and D). Additional
assays using BMC from female mice were not performed for ethical rea-
sons, as there was no signiﬁcant impact of CD59a ablation upon osteo-
blast differentiation in male mice.
4. Discussion
There are several ways in which cells can protect themselves from
complement activity. In humans, CD59 is unique as it is the only com-
plement regulator that controls MAC assembly by preventing lytic
pore formation. In mice, CD59a performs these functions [27] and it is
expressed in almost all tissues [9,18]. CD59a gene deﬁciency
Fig. 6. Increased osteoclastogenesis in CD59a-deﬁcient mice in vitro. Osteoclast differentiation assays were conducted with RANKL-induced primary BMC frommale and female WT and
CD59a−/−mice at 8–10 weeks of age. (A) Representative images of TRAP-negative control samples stimulated with M-CSF only and TRAP-positive cultures stimulated with M-CSF and
RANKL (multinucleated cells [MNCs], arrow). Scale bar (black), 0.25 mm. (B) Quantiﬁcation of TRAP-positive MNCs produced from RANKL-induced cultures. Culture supernatants of
cells grown in M-CSF only and M-CSF and RANKL from male mice were harvested and mKc concentrations were measured by ELISA in WT (black bars) and CD59a−/− (white bars)
samples. (C) Osteoblasts were generated from enriched primary osteoprogenitor cells from male mice and, after 14 days in mineralisation medium, stained for ALP and Alizarin red.
Representative images are shown. (D) ALP and Alizarin red coverage of wells was quantiﬁed. All values are mean ± SEM of triplicate cultures from at least ﬁve separate mouse bone
marrows for each group at 8–10 weeks of age. ⁎P b 0.05; ⁎⁎P b 0.01; ⁎⁎⁎P b 0.001 versus WT cultures.
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as atherosclerosis, neuropathology, and importantly, for this study, ar-
thritis [24,28,29]. In each case, the contribution of the terminal pathway
of the complement system and MAC assembly to tissue injury is in-
creased in the absence of CD59a. Herewe tested the effects of CD59ade-
ﬁciency on bone homeostasis to develop an understanding of how
CD59a might inﬂuence normal bone and joint architecture. Our results
indicate that normal bone homeostasis and structure is disrupted in
the absence CD59a, which could explain the susceptibility of CD59a-
deﬁcient mice to develop both spontaneous and exacerbated arthritis
[15,24]. This indicates that complement regulator CD59a is required
for maintenance of normal bone homeostatic functions.
The complement system is a central element in host defense, clear-
ance of immune complexes, and tissue homeostasis. The less known
regulatory roles of the complement system on bonemetabolism and re-
pair were reviewed recently [30]. Both clinical and experimental data
clearly suggest a crucial function of complement in disorders affecting
bone and in bone regeneration; however, the underlying molecular
mechanisms remain unclear. We consider that the actions of CD59a
on MAC formation and on bone cell activities are one and the same.
The inﬂuence of MAC on a variety of cell types is well characterised
[31–33]. Since MAC triggers a range of activation events in diverse cell
types, the effects revealed here by CD59a deﬁciency on bone cells add
to the list of non-lethal actions of MAC. The fact that the complement
system in male mice raised on the C57BL/6J background is more active
compared to females supports this contention [18,34,35]. The expectedimpact of heightened complement activation on a background of CD59a
deﬁciency would be greater in males. Here, structural changes in bone
were more profound in male mice supporting the hypothesis. There
are several inﬂammatory joint diseases (e.g. OA, systemic lupus erythe-
matosus, and rheumatoid arthritis) where clinical data revealed higher
intrinsic complement activity and complement-associated pathology
that may also affect bone [15,36,37].
Although femoral length increased with age in male and female WT
and CD59a−/− mice, femurs of male CD59a−/− were longer (8 and
20 weeks) and thicker (8 weeks) compared to WT mice, despite little
difference in overall body weight. No such difference was observed in
female mice. Male CD59a−/−mice have increased complement activity
compared to females and consequently greater intravascular
haemolysis and erythrocyte turnover [18]. However, heightened com-
plement activity in male mice is not limited to CD59a deﬁciency. This
is why male mice are frequently chosen for studying complement-
mediated diseases in experimental models [24,38]. In male mice, the
impact of the increased complement activity is likely greater in the ab-
sence of CD59a than in WT mice where the effect of the terminal com-
plement pathway is regulated [29]. There is also the differing nature
and level of circulating sex hormones that deﬁne male and female
mice at different ages. Oestrogen, for example, is a major player in
bone homeostasis [39]; it can inhibit osteoclastogenesis and osteoclast
activity. Furthermore, oestrogen acts on osteoblast precursor cells in-
creasing or decreasing their expansion and maturation [39]. In diseases
such as OA and osteoporosis, oestrogen may have a protective effect;
260 A.C. Bloom et al. / Bone 84 (2016) 253–261women with low levels of estradiol were signiﬁcantly more likely to
develop radiographically deﬁned OA than women with higher levels
of estradiol [40]. Hence, the gender-speciﬁc bone phenotype reported
here likely resulted from the combined protective effect of oestrogen
in females and exacerbated impact of enhanced complement activity
in male CD59a−/−mice.
Alterations to femoral cortical bone architecture were observed in
male CD59a−/−mice. Speciﬁcally, cortical bone volume (cBV) was sig-
niﬁcantly increased (8 and 20 weeks) while bone mineral density
(BMD) was reduced. This implies that osteoblast-dependent bone ma-
trix apposition exceeds the rate of bone-matrix mineralisation, or that
osteoclast-dependent resorption of mineralised bone could exceed the
mineralisation rate. Both would result in a larger, albeit softer, bone
mass. The altered bone remodelling in male CD59a−/−mice is also ap-
parent in the overall increase in: the number and thickness of bone tra-
beculae, the fraction of trabecular bone volume (TV) that is occupied by
mineralised bone (BV), and mineral apposition rate (MAR) (8 and
20 weeks). The alterations in bone remodelling can be explained
through the action of the MAC; the increased haemolytic activity and
erythrocyte turnover seen inmale CD59a−/−mice could impact this di-
rectly. However, aside from its role in the generation of a lytic pore,MAC
also drives cell activation and proliferation in several contexts, inducing
pro-inﬂammatory cytokine production and Th1 cell polarisation as
examples [41]. These responses may indirectly impact upon bone
homeostasis by altering osteoclastogenesis, as reported in
inﬂammation-induced activation of T-cells; which up-regulate
RANKL, enhancing osteoclastogenesis and bone erosion [42].
To further understand the subtle inﬂuence of CD59a gene deletion
upon bone remodelling, osteoblast and osteoclast activity was assessed
in situ and differentiation assays were performed ex vivo. Whereas his-
tological data showed up-regulation of osteoclast resorption surface
and mineral apposition by osteoblasts conﬁrming increased bone re-
modelling, osteoblast maturation assays ex vivo were not affected in
male CD59a−/−mice. However,male CD59a−/− bonemarrow cells pro-
duced signiﬁcantly more osteoclasts than WT controls cultured under
identical conditions (with RANKL and M-CSF), suggesting that osteo-
clasts are the main driver of the altered bone phenotype in CD59a−/−
mice or that mouse osteoblasts do not express CD59a and are normally
unresponsive to activation by the terminal complement pathway. The
membrane-bound regulatory protein CD59 is expressed in human oste-
oblasts and osteoclasts [11]; however, expression data in mouse have
not been reported previously. Here we show for the ﬁrst time that oste-
oclasts, bone tissue (femur), and calvarial osteoblasts maintained in
monolayer culture or as a 3D construct to obtain an osteocyte pheno-
type express CD59a (see Supplementary Figure S2). Interestingly, the
alterations in osteoclastogenesis were also gender speciﬁc ex vivo,
mirroring in vivo ﬁndings. Ex vivo cultures are removed from protective
effects of oestrogen, but the precursor cells may already be primed to-
wards a speciﬁc functional fate. Aguila et al. identiﬁed gender-speciﬁc
responses to IL-7 in ex vivo cultured bone marrow cells. The authors
saw reduced myeloid precursors with osteoclastic developmental po-
tential in females, but not in males. The authors also suggest that this
could be due to hormonal modulation of hematopoiesis [43]. Nadaka
et al. described that murine haematopoietic stem cells divide more fre-
quently in females and is dependent on oestrogen produced in the ova-
ries [44]. Therefore, it is likely that oestrogen or other sex hormones
inﬂuence haematopoietic precursor cells in CD59a-deﬁcient mice, but
this remains to be investigated. All ex vivo experiments were conducted
in the absence of exogenous complement (heat-treated serumwas used
throughout) suggesting either that 1) there is an intrinsic difference be-
tween the CD59a−/− versus WT bone marrow cell responses in culture
that is not linked to complement activation or MAC assembly, or 2) the
cells produce complement proteins in culture. Bone homeostasis relies
upon cross-talk between mesenchymal-lineage bone-forming osteo-
blast and hematopoietic-lineage bone-resorbing osteoclasts; our data
suggest that osteoclasts orchestrate increased bone remodelling inmale CD59a−/−mice. A view that is also supported by the elevated plas-
ma levels of carboxy-terminal collagen crosslinks (CTX-I) and
osteocalcin (Supplementary Figure S1). Final conclusions may not be
drawn until lineage-speciﬁc knockouts have been generated and their
bone phenotype analysed.
Mechanistic clues may be derived from secreted factors where mKc
and OPN stood out. CD59a−/− osteoclasts in vitro had increased mKc
production, possibly due to an increased activation state. The cytokine
mKc is a potent neutrophil chemotractant [45], and its presence
in vivo is indicative of tissue inﬂammation [46]. mKc and its receptor
CXCR2 are also involved in bone development [26]. CXCR2 is highly
expressed in haematopoietic cells [47] and osteoclast precursors; there-
fore, release of mKc could trigger autocrine fusion of osteoclast precur-
sor cells tomature osteoclasts, potentially enhancing their function [48].
Moreover, mKc secretion by osteoblasts and the recent demonstration
that this chemokine regulates bone marrow macrophage (osteoclast
precursors) trafﬁcking endorse a functional role for mKc in modulating
bone physiology [26,49]. Increased tissue expression of OPN was ob-
served in bones fromCD59a−/−mice. Aberrant expression of OPN is as-
sociated with abnormal bone mineralisation [50] and enhanced
osteoclast-dependent pit formation [51]. How CD59a targets these me-
diators remains to be investigated.
The possibility remains that expression of complement components
such as C3, C5, and their respective receptors by primed osteoclasts and
osteoblasts [7,10,11] also contribute to the bone phenotype observed in
male CD59a−/−mice. To formally test these ideas, a substantial body of
additional research is needed. Nevertheless, our study provides evi-
dence that complement regulator CD59a can control normal bone ho-
meostasis and is needed for the formation of strong bone morphology.
The absence of CD59a can exacerbate bone diseases such as arthritis
[15,24], and our study presents the possibility that these phenotypes
are compounded by weaker homeostatic bone structures that exist be-
fore disease commencement. Increased understanding of complement
control of homeostatic functions may allow us to tease apart mecha-
nisms related to health or disease.
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